- Clinical phase I studies were initiated during January 2008 with product candidate BI-
 204 for treatment of atherosclerosis.
  
 - The first individuals were included during January 2008 in the phase I programme with   
 product candidate TB-403 for treatment of cancer.

 - Data indicating the therapeutic potential of TB-403 were published in the respected scientific publication, Cell.
       
 - Clinical Phase I studies of the drug candidate TB-402 for the prevention of blood clots   
 have been successfully completed. Decision taken to advance into Phase II clinical development.
   
 - New drug candidate, BI-505, was selected. The first step will be to develop it for 
 treatment  of hematologic cancer.
  
 - A directed new share issue was successfully carried out in July, raising SEK 120.0 million for BioInvent after issue expenses while broadening ownership with four new institutional owners. 

- Collaboration with Genentech, Inc., to co-develop and commercialize the product candidate BI-204 was initiated in January 2007. A first instalment of SEK 105.5 million was received.

- Net revenues for January - December 2007: SEK 143.4 million (50.8).

- Cash flow from current operations and investment activities for January - December 2007 showed a surplus of SEK 8.7 million (-107.3).

- Current investments together with cash and bank as of 31 December 2007: SEK 216.9 million (88.0).

- Profit after tax for January - December 2007 amounted to SEK -16.1 million (-108.8) and the profit after tax per share was SEK -0.31 (-2.31).

BioInvent is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company is currently running innovative drug projects within the areas of thrombosis, cancer, atherosclerosis and ophthalmic diseases.

Comments by the CEO
BioInvent has had a very successful 2007. We have made great advances both commercially and in the projects. We currently have three projects in clinical phase and one in preclinical development, the step prior to clinical phase. With such progress we are now well positioned with a broad and well-diversified project portfolio. Our strategy works and we are firmly committed to continuing on this well-trodden path - expand the portfolio and integrate forward in the value chain, carefully balanced with partner agreements to ensure that the projects receive the necessary funding and competence.

Our projects also represent state of art in terms of research, with several innovative medical concepts.

BI-204 for the prevention of heart attack or stroke in high-risk patients, may become the first medication to address the inflammatory processes resulting in plaque rapture causing heart attacks.

Our angiogenesis inhibitor TB-403 blocks vessel growth in tumours without injuring normal vascular formation, creating an opportunity to launch a strong competitor to the current treatment, which also affects normal vascular formation.

The anticoagulant TB-402 addresses the problems associated with prevention of blood clots: safety and the risk of uncontrolled bleeding. So far the clinical development programme has provided good indications that TB-402 can be developed into a safe long-acting anticoagulant.

Our most recent drug candidate, BI-505, has demonstrated improved ability to kill tumour cells in severe forms of cancer, such as multiple myeloma, compared with currently available treatment strategies for this type of tumour. These encouraging preclinical results make us look with confidence to the planned clinical studies for BI-505.

 BI-505 is also the result of our own discovery research. Uptil the designation of this candidate our projects have been based on medical concepts recruited from external research groups. We identified BI-505 and its target protein through a screening system developed in house. We are currently looking at new opportunities for a broader use of this technology in our research.     

Contact
Any questions regarding this report will be answered by:

BioInvent International AB (publ.)
Svein Mathisen, President & CEO, tel.+46 (0)46 286 85 67, mobile +46 (0)708 97 82 13
Cristina Glad, Executive Vice President, tel. +46 (0)46 286 85 51, mobile +46 (0)708 16 85 70.

College Hill
Gemma Price, Holly Griffiths, Katja Stout, tel. +44 (0)20 7457 2020
The report is also available at www.bioinvent.com